WON Tech makes laser and energy-based medical solutions, and most of its revenue comes from its skin aesthetic medical device segment. In Q1 2026 that segment generated KRW 39.2 billion of the KRW 40.2 billion total, or 97.5%, according to company-released figures.
By product, Oligio series equipment accounted for KRW 19.8 billion, laser equipment such as Picocare, Lavieen and Sandro Dual for KRW 12.0 billion, and consumable tips for KRW 7.4 billion.
The Oligio line is a noninvasive lifting device using RF energy, and its consumable sales following equipment placements are described as the core of its earnings base. Exports reached KRW 31.2 billion in Q1 2026, or 77.5% of revenue, and the 2025 export share was 70.0%.
Overseas operations are organized across four corporate subsidiaries in the United States, Japan, Thailand and China, and press reports said the Thailand unit grew 130.2% in 2025 to KRW 37.2 billion.
Regulatory approvals rest on the US FDA and EU CE marks, and 2026 brought further product approval news from Canada, Vietnam, Mexico and Taiwan.
At CES 2026 in January the company unveiled a noncontact vital-sign measurement solution and a combined laser and electrical stimulation pain therapy device, extending its scope toward healthcare.
The competitive field is the domestic energy-based aesthetic device market, particularly RF lifting, and the Korea Exchange named WON Tech a new 2026 KOSDAQ Rising Star, citing that position.